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Abstract
Gasdermin B (GSDMB) belongs to the Gasdermin protein family that comprises four members (GSDMA-D). Gasdermin B
expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-
expression has been related to tumor progression. At least four splicing isoforms of GSDMB have been identified, which may
play differential roles in cancer. However, the implication of GSDMB in carcinogenesis and tumor progression is not well
understood. Here, we uncover for the first time the functional implication of GSDMB in breast cancer. Our data shows that
high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients
included in an expression dataset (.1,000 cases). We demonstrate that GSDMB is upregulated in breast carcinomas
compared to normal breast tissue, being the isoform 2 (GSDMB-2) the most differentially expressed. In order to evaluate the
functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2). The overexpression
of both isoforms in the MCF7 breast carcinoma cell line promotes cell motility and invasion, while its silencing in HCC1954
breast carcinoma cells decreases the migratory and invasive phenotype. Importantly, we demonstrate that both isoforms
have a differential role on the activation of Rac-1 and Cdc-42 Rho-GTPases. Moreover, our data support that GSMDB-2
induces a pro-tumorigenic and pro-metastatic behavior in mouse xenograft models as compared to GSDMB-1. Finally, we
observed that although both GSDMB isoforms interact in vitro with the chaperone Hsp90, only the GSDMB-2 isoform relies
on this chaperone for its stability. Taken together, our results provide for the first time evidences that GSDMB-2 induces
invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic
marker in breast cancer.
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Introduction
Gasdermin protein superfamily (PF04598) is constituted of eight
structurally-related genes in the mouse (Gsdma1, Gsdma2,
Gsdma3, Gsdmc1, Gsdmc2, Gsdmc3, Gsdmc4, Gsdmd), and four
genes in human: Gasdermin A (GSDMA), Gasdermin B (GSDMB),
Gasdermin C (GSDMC) and Gasdermin D (GSDMD) [1–11]. GSDMB
(previously known as PRO2521, GSDML) seems to have originated
from a duplication of GSDMA gene during the evolution of this
gene family, being the only GSDM member not present in the
rodent genome [10]. The identification of mouse Gsdma3 as the
gene responsible for an abnormal skin phenotype (epidermal
hyperplasia, hyperkeratosis, and abnormal hair development) of
two mutant mice led to the characterization of the Gsdm gene
family [1,2]. Gsdm genes have a tissue-specific expression pattern in
gastric epithelia and epidermis, suggesting that they may
contribute to the regulation of normal epithelial cell proliferation
and /or differentiation [11]. However, there is scarce information
about the expression pattern of human GSDM genes.
Although the four human proteins of this family contain several
conserved sequences in the N- and C- terminal regions, to date no
functional domains or motifs have been described. Consequently,
the biological function of these proteins in physiological and
pathological situations is still largely unknown. Recently, genetic
polymorphisms in the loci containing GSDMB and GSDMA genes
have been correlated with childhood asthma susceptibility [12],
but the potential functional role of these genes in this pathology
remains to be uncovered.
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Interestingly, the altered expression of GSDM genes has been
also associated to cancer. GSDMA is frequently found down-
regulated in human gastric and skin cancer tissues and cancer-
derived cell lines [4,5]. Furthermore, GSDMA is involved in the
TGF-beta signaling mediating the apoptotic activity in the gastric
epithelium [4]. In contrast, GSDMC over-expression is associated
with an increase in the metastatic potential in melanoma cell lines
[6] and GSDMD expression is observed in the majority of gastric
cancers [5].
GSDMB expression has been described in human gastric, liver
and colon cancer cell lines and carcinomas, as well as in normal
tissues [7]. GSDMB over-expression has been described in gastric
and cervical tumors compared with normal tissue and this
alteration is associated to tumor progression [7,8]. GSDMB is
located in the same chromosomal region than GSDMA; however,
their expression is neither overlapping nor complementary during
cancer development and progression [9]. The comparative
analysis of these proteins suggests that GSDMA may act as tumor
suppressor gene in gastric cancer, while GSDMB could be
considered as an oncogene based on its amplification and over-
expression in this cancer type [5]. Although GSDMB expression
has been reported in the secretory cells in gastric and hepatic
carcinomas [7], there are some discrepancies in its expression
pattern depending on the tissue or cell system analyzed [7,8].
There are also evidences that GSDMB presents different splicing
variants that may have differential effects on tumor growth and
development [7,8]. Four different isoforms have been described,
which differ in exons 6 and 7 of the GSDMB gene (Figure S1) [7,8].
However, the relevance and specific functional role of these
variants in cancer is still unknown.
Based on these data, we investigated the potential role of
GSDMB in breast cancer. The analysis of GSDMB expression in a
dataset of more than 1,000 human breast cancer tumors reveals
that high levels of expression are correlated with reduced survival
and increased metastasis. Our in vitro analysis in MCF7 cells over-
expressing GSDMB-1 and -2 isoforms reveal common and distinct
functions of these GSDMB variants in breast cancer progression.
While both GSDMB isoforms promote cell motility and invasion
through activation of the Rho-GTPases Rac-1 and Cdc-42 in vitro,
their analysis in xenograft mouse models showed that only
GSDMB-2 increases tumor growth and metastasis. Moreover,
silencing the endogenous GSDMB in HCC1954 breast carcinoma
cells reduces their migratory and invasive capacity. Finally, we
report that GSDMB-2 is a novel client protein of Hsp90, since its
stability relies on this chaperone. Our data indicate for the first
time that GSDMB, and specifically the isoform 2, is a new marker
of breast cancer progression and a potential therapeutic target in
order to block tumor growth and cell dissemination.
Materials and Methods
Breast samples
We studied a series of 18 sporadic ductal breast carcinomas, (6
of them classified as grade 1, 7 as grade 2 and the rest as grade 3)
as well as 4 normal breast samples obtained from the Biobank of
the MD Anderson Cancer Center Madrid, Spain. Patients
underwent surgery between 2011 and 2012. The mean patient
age at surgery was 57.3 years (range, 45 to 81 years). This study
was performed following standard ethical procedures of the
Spanish regulation (Ley de Investigacio´n Orga´nica Biome´dica,
14 July 2007) and was approved by the ethical committee of the
MD Anderson Cancer Center Madrid, Madrid, Spain.
Cloning human GSDMB
Universal Human Reference RNA (Stratagene) was used for
isolating GSDMB cDNA. First strand cDNA was made using
Superscript II reverse transcriptase (Invitrogen) with oligo dT. The
full-length coding regions of GSDMB-1 (NM_001042471.1) and
GSDMB-2 (NM_018530.2) were amplified by PCR using gene-
specific primers (Forward: 59-GGGGGATCCATGTTCAGCG-
TATTTGAGGAAATC-39; and Reverse: 59-
GCCTACCTCTGTCTCTTCCCTCGAGGGG-39. Amplifica-
tion reactions consisted of the following steps: 95uC for 5 min,
35 cycles at 95uC for 30 sec; 55uC for 1.5 min and 72uC for
10 min. The coding regions of both isoforms were cloned into the
Bam HI and Xho I sites of plasmid pcDNA3-HA (Invitrogen). Full-
length cDNA of human GSDMB-1 and -2 subtypes were
confirmed by restriction mapping and DNA sequencing.
Cell culture and reagents
Human carcinoma cell lines, MCF7, MDA-231, CAMA-1,
T47D, HCC1954, HEK293T (human embryonic kidney 293
transformed with T-antigen) and non-tumorigenic breast cell line
MCF10-2A were obtained from the American Type Cell Culture
(ATCC) (LGC Standards-SLU) and cultured according to the
indicated supplier conditions. Cell lines were authenticated using
STR-profiling according to ATCC guidelines. Cells were main-
tained as monolayer cultures at 37uC in an atmosphere with 5%
CO2. For generation of MCF7 over-expressing GSDMB-1 and -2
GSDMB variants the indicated cell lines were transfected using
Lipofectamine (Invitrogen) with pcDNA3-GSDMB-1 (MCF7-G1)
and -2 (MCF7-G2) tagged with hemagglutinin epitope (HA) at the
C-terminal respectively, and independent clones were isolated with
cloning rings in the presence of G418 (400 mg/ml) for 3-4 weeks.
Control cells (MCF7-C) were obtained by stable transfection of
empty pcDNA3-HA vector. At least 10 independent clones were
isolated from each transfection. Two independent clones from
each transfection were analysed and most representative results of
one single clone are shown in the figures. MCF7 cells expressing
mCherry (MCF7-mCherry) or firefly luciferase cells (MCF-Luc)
were obtained by lentiviral infection with PRRL-cPTT-PGK-
mCherry-W or GFP-luc viral particles (Gentarget Inc) respective-
ly.
GSDMB silenced HCC1954 cells were obtained using Mission
shRNA Lentiviral Transduction Particles (SIGMA-Aldrich). Two
GSDMB shRNA sequences were validated: TRCN0000137108
(sh108) and TRCN0000168794 (sh794). Non-targeting Control
shRNA Transduction Particles (SHC002V) were used as control.
The Hsp90 inhibitor 17-AAG (Sigma) was dissolved in DMSO
to a stock concentration of 1 mM. MCF7 control, GSDMB-1 and
GSDMB-2 over-expressing cells were treated with different
concentration of 17-AAG (1,000, 500, 100, 50 nmol/L) or DMSO
for 24 hours. Lysates were blotted with rabbit anti-Hsp90 (Cell
Signalling), rat anti-HA (Roche) or mouse anti-tubulin (Sigma)
antibodies.
The Rac1 inhibitor NSC23766 (TOCRIS) was dissolved in
distilled water to a stock concentration of 100 mM. Migration
assays were performed using modified polycarbonate nucleopore
membranes (6.5 mm in diameter, 8-mm pore size) (Corning, USA).
Cells (16105) were seeded on the upper part of each chamber in
the presence of this inhibitor (100 mmol/L), and after incubation
for 48–72 h, non-migrating cells on the upper surface of the filter
were wiped with a cotton swab, and migrated cells on the lower
surface of the filter were fixed, stained with DAPI, and counted by
examination of at least six microscopic fields.
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Semiquantitative and quantitative RT-PCR analysis
Total RNA from cell lines and tumor samples was extracted
with Trizol (Invitrogen) and RNaesy Extraction Kit (QIAGen) as
indicated by the manufacturer. cDNA from the different cell lines
and tumor samples was obtained from 1 mg of total RNA using
random primers and Superscript II system (Life Technologies Inc)
as previously described [13]. Gene expression analyses were
performed by semiquantitative RT-PCR (sqRT-PCR) and real
time RT-PCR (qRT-PCR). For qRT-PCR pre-designed TaqMan
probes (GSDMB, GSDMB-1, GSDMB-2, GSDMB-3&4) or
SybrGreen PCR reagents (mCherry) (Sigma) were used on an
iQ5 iCycler Realtime PCR Detection System (BioRad) using
TaqMan ‘‘iQ Supermix’’ or ‘‘SYBR Green Supermix’’ (BioRad),
according to the manufacturer’s recommendations. GSDMB-3
and -4 were analyzed together as there is no commercially
available Taqman probe to discriminate isoform 3. Primers
sequences and amplification conditions for sqRT-PCR and for
qRT-PCR are indicated in Tables S1 and S2, respectively. All
RT-PCRs were performed in triplicates. Relative expression was
normalized to b2 microglobulin, b-actin or GAPDH. The
comparative threshold cycle (Ct) method was used to calculate
the amplification factor as specified by the manufacturer.
Barrier Migration Assay and Immunofluorescence
For barrier migration assay, cells were grown to confluence on
10 mm glass coverslips as previously described [24]. The barrier
assay was performed incubating the coverslips on chambers (Lab-
Tek, Nunc) and cells were cultured for at least 5 days at 37uC in an
atmosphere with 5% CO2. For the immunofluorescence analysis
the cells were fixed in 4% formaldehyde at room temperature for
15 minutes and permeabilized for 5 minutes using 0.5% Triton X
100 (Sigma). After washing, cells were incubating with Alexa-647–
coupled phalloidin (Molecular Probes) to stain F-actin. Cell nuclei
were stained using 4,6-diamidino-2-phenylindole (DAPI, Molec-
ular Probes). For the rest of inmunofluorescence assays, after
fixation, permeabilization and blocking (256105 cells/coverslip)
cells were incubated with first and secondary antibodies for 1 hour
at room temperature. Primary antibodies were: rat anti-HA 1:250
(Roche); mouse anti-tubulin 1:4000 (Sigma), and mouse anti-Rac1
1:100 (BD Transduction). Secondary antibodies were goat anti-
mouse (1:1000), anti-rat (1:5000) conjugated with Alexa-488,
Alexa-594 or Alexa-647 (GE Molecular Probes). For tissue
immunofluorescence, mice lungs tissues were fixed in a mix of
2% PFA and 20% sucrose overnight and cryo-embedded in Tissue
Tek O.C.T. embedding compound. Sections (5 mm) were stained
with DAPI and mCherry positive cells were detected by their
intrinsic signal. In all cases fluorescent images were obtained using
a Leica TCS SP5 confocal microscope (x63 objetive) and analyzed
using the Leica LAS AF software. Digital images of mCherry
stained sections were analyzed and pixels were quantified with
ImageJ Software (NIH). Phase-contrast images of the indicated
cells were taken using an inverted Zeiss Axiovert microscope.
Invasion assay
Invasion assays of the indicated cell lines were performed using
modified Boyden chambers with polycarbonate nucleopore
membranes (Corning, USA). Filters (6.5 mm in diameter, 8-mm
pore size) were coated with Matrigel as previously described
[13,14]. In brief, cells (16105) were seeded on the upper part of
each chamber, and after incubation for 24 h, non-invading cells
on the upper surface of the filter were wiped with a cotton swab,
and migrated cells on the lower surface of the filter were fixed,
stained with DAPI, and counted by examination of at least five
microscopic fields.
Fluorescent gelatin substrate degradation assay
Gelatin-FITC substrate (Invitrogen) was prepared as previously
described [15]. Cells (256103) were placed on coverslips (Lab-Tek,
nunc) previously covered with fluorescent gelatin substrate and
incubated in RPMI with 10% fetal bovine serum (FBS) at 37uC in
an atmosphere with 5% CO2 overnight. The cells were fixed and
permeabilized with 4% paraformaldehyde and 0.05% Triton X-
100 respectively for 5 min each, washed with PBS and actin was
visualized by staining with Alexa Flour-647 Phalloidin (Invitrogen)
for 30 min and nuclei were stained with DAPI followed by washes
with PBS. Confocal microscopy analyses were performed using a
Leica TCS SP5 confocal microscope, x63 objective. Degradation
area was calculated by dividing the total area of the degraded
zones per cell by the number of cells presents in each field using
the ImageJ program.
Gelatin Zymography
To evaluate the activity of MMP-2 and -9 activity cells were
cultured in serum-free RPMI for 24 hours. Briefly, samples were
prepared with standard SDS-gel-loading buffer containing 0.01%
SDS without b-mercaptoethanol and heating. The samples were
subjected to electrophoresis SDS-PAGE in 8% gels containing
0.1% gelatin. Following electrophoresis, the gels were washed in
2.5% Triton X-100 at room temperature to remove SDS,
incubated in 100 mL reaction buffer (40 mM Tris-HCl, pH 8.0,
10 mM CaCl2, 0.02% NaN3) for 24 h at 37uC and stained with
Coomassie brilliant blue R-250 containing 50% methanol and
10% acetic acid. Gelatinolytic activities were visualized by
negative staining with 20% methanol and 10% acetic acid. All
samples were analyzed in duplicate. Finally, the gels were scanned
and subjected to densitometry analysis using Image J software.
Relative density was calculated by dividing the intensity of the
active MMP-9 band by the pro MMP-9 band, and then
normalizing the data to the corresponding bands in the control
cells.
Proliferation assays
2.56104 cells were grown into 96-wells plate according to Cell
Proliferation ELISA, BrdU (colorimetric) kit, (Roche Diagnostic
SL, Basel, Switzerland) using the manufacturer’s recommenda-
tions. Alternative, alamarBlue assay (Thermo Scientific) was
performed according to the manufacturer’s protocol to analyze
the proliferation of shGSDMB and shControl- HCC1954 cells.
Analysis of Rho-A, Rac-1 and Cdc-42 activity
To detect Rho-A-GTP, Rac-1 (Rac-1-GTP) and Cdc-42 (Cdc-
42-GTP) in cell lysates, we used a Rho-A Activation Assay Kit (17-
294) and Rac-1/Cdc-42 Activation Assay Kit (17-441, Millipore),
using the manufacturer’s instructions.
Subcellular fractionation assay, Western Blotting and
Immunoprecipitation
For subcellular distribution of endogenous GSDMB, HCC1954
cells were harvested and fractionated using the Subcelullar Protein
Fractionation Kit according to manufacturer’s protocol (Thermo
Fisher, Rockford, IL). For Western blotting, cells were lysed and
proteins were extracted using standard RIPA buffer. Protein
concentration was determined by BCA protein assay (Pierce,
Rockford, IL, USA), and equal amounts of proteins were loaded in
SDS–PAGE in 6–12% gels. Polypeptides were transferred onto
Immobilon-P (Millipore) nitrocellulose membranes, and nonspe-
cific binding was blocked with 5% nonfat dry milk. Immunoblots
were incubated with the indicated antibodies: rat polyclonal anti-
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HA (Clone 3F10, Roche), 1:500; mouse monoclonal anti-tubulin
(T9026, Sigma), 1:10.000; anti-GAPDH (MAB374, Millipore),
1:50.000; anti-GSDMB (3D8, Santa Cruz), 1:250; anti-High
Molecular Weight Cytokeratins (CKs 1, 5, 14,17) (clone 34BE12,
DAKO), 1:100; rabbit polyclonal anti-Hsp90,(C45G5,Cell Sig-
nalling), 1:1000; anti-Calnexin, (C5C9, Cell Signaling), 1:1000;
anti-Trimethyl (Lys4) HistoneH3 (Mab07473, Millipore), 1:1000;
anti-Akt 1:1000 (9272, Cell Signaling), and goat anti-Snail2 (G-18,
Santa Cruz); 1:250. Secondary antibodies were HRP-coupled
sheep goat anti-rat (1:10000), anti-mouse (1:1000) or anti-rabbit
(1:5000) (Amersham). Bands were visualized using ECL chemilu-
minescence kit (Amersham), quantified by densitometric scanning
and normalized to b-actin or a-tubulin expression.
For immunoprecipitation, cells were lysed in a buffer containing
10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, and
1 mM PMSF. 1 mg of protein containing lysate was incubated
with appropriate antibody overnight and then with protein A/G-
sepharose for 1 hr at 4uC. After washing the beads with the lysis
buffer three times, the protein bound to the beads was detected by
Western blotting.
Mammary fat pad inoculation and intracardiac
experimental metastasis model
For primary tumor induction and spontaneous metastasis
assays, MCF7-C and GSDMB-1 and -2 mCherry or Luciferase
positive cells were orthotopically injected (56106 in 0.1 ml serum
free growth medium) into the left fifth mammary fat pad (mfp) of
five 8-week female nu/nu mice (Charles River) for each
experimental condition (mCherry and Luc systems) as described
in [14]. Tumor growth was measured once per week by
determination of the two orthogonal external diameters using a
calliper. Volumes were calculated using the formula (4p/3)xL
xW2, where L and W are the length and the width of the tumours
xenografts respectively. Tumors were surgically excised at 33
weeks post injection (p.i.) and processed for histology. For
spontaneous metastasis assay, mice were euthanized at the end-
point of the experiment, and lungs were analyzed for mCherry
expression.
For experimental metastasis assays, a group of 10 female nu/nu
mice (Charles River) aged 7 weeks, were inoculated with MCF7
control, GSDMB-1 and GSDMB-2 cells (16105 in 0.1 ml sterile
PBS) stably expressing the protein luciferase into the left ventricle
of the heart by nonsurgical means. A successful intracardiac
injection was indicated on day 0 by images showing systemic
bioluminescence distributed throughout the animal. Only mice
with evidence of a satisfactory injection continued in the
experiment. Live animal bioluminescence optical imaging was
performed as described [16] using the IVIS Spectrum system or
the IVISR Lumina II system (Caliper, Xenogen). Measurements
were taken weekly starting 1 week after injection. At the end-point
of the experiments, mice were euthanized 5 min later of in vivo
bioluminiscent measure, and organs were analyzed for luciferase
expression. Data were quantified with the Living Imaging software
4.2 (Xenogen Corporation). Mice were housed and maintained
under specific pathogen-free conditions and used in accordance
with institutional guidelines and approved by the Committee for
Animal Care from the Universidad Autonoma de Madrid (UAM).
To validate GSDMB expression in primary tumors an
immunohistochemical staining was performed using LSAB meth-
od (Dako) with a heat-induced antigen retrieval step. Sections were
immersed in boiling 10 mM sodium citrate at pH 6.5 for 2 min in
a pressure cooker and rat anti-HA antibody (Roche) was used. The
primary antibody was omitted in the negative controls. GSDMB
staining was defined as positive for those samples with more than
5% of GSDMB-expressing tumour cells.
Survival analysis in breast cancer gene expression
datasets
To study the clinical value of GSDM genes in breast cancer, we
retrieved from the public database ROCK (http://rock.icr.ac.uk)
the gene expression data and its associated clinical information of
the Cancer Genome Atlas Network (TCGA) study [17]. The
normalized expression of GSDM gene probes (GSDMA:
A_23_P152605; GSDMB: A_23_P66451; GSDMC:
A_23_P60116; and GSDMD: A_24_P363738) was available for
534 breast cancer samples. For each of these genes, tumors were
categorized as having "high expression" if the gene expression
value was within the third percentile (top 25% expression from all
the samples); otherwise they were categorized as "low". Overall-
survival Kaplan Meier curves were generated and differences in
survival were assessed by Log-rank test (p,0.05 considered as
statistically significant) using GraphPad PRISM 4.0.
Additionally, we performed a combined analysis on six
expression microarray datasets of breast cancer samples with
clinical data [18-23]. Data from these studies were extracted from
the wider microarray compilation by Ur-Rehman et al provided in
the ROCK database. All these studies were carried out on the
HG-U133A platform manufactured by Affymetrix, and data was
subject to quality control and RMA normalization, as detailed in
ROCK (http://www.rock.icr.ac.uk/search/viewSampleDetails2.
jsp?projectid = 196&manufacturer = Affymetrix). Next, the nor-
malized expression values of GSDMB probe (219233_s_at) were
median centered, and categorized as "high" when they were within
the third percentile (top 25% expression). For survival analysis,
tumors with disease free survival data (n = 1094, median follow-up
time = 85 months) and distant metastasis free survival (n = 902,
median follow-up time = 87 months) were selected and analyzed
by Log-rank test.
Statistical analysis
Data were tested for normality and paired sets of data were
compared using paired Student’s t-test (two tailed). Comparisons
between multiple treatment groups from the same experiment
were made using one-way ANOVA. When significant differences
were found between groups, Bonferroni posttest was used to test
significance. In all cases values of p,0.05 were considered
statistically significant. These analyses were carried out using the
GraphPad PRISM 6.0 software.
Results
GSDMB over-expression is associated to poor prognosis
in breast carcinomas
To evaluate the potential relevance of Gasdermin genes in breast
cancer, we first tested whether their levels of expression were
associated with breast cancer prognosis. We performed survival
analyses based on their expression in a large series of breast
carcinomas using publicly available gene expression dataset
(Figure S2). The analysis in the TCGA dataset, comprising 534
breast cancers [17] evidenced that patients with tumors expressing
high levels of GSDMB showed a significant reduction in overall
survival (p= 0.018), while we could not find any association with
prognosis for the other members of the family (Figure S1). To
explore further the clinical relevance of GSDMB expression in
breast cancer, we realized an in silico study combining six breast
cancer profiling datasets performed on the HG-U133A Affymetrix
microarray platform [18–23]. This analysis demonstrated that
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high levels of GSDMB expression were significantly associated with
poor disease outcome, in both disease free survival (DFS,
p,0.0001) and distant metastasis free survival (DMFS,
p,0.0001) (Figure 1A).
Next, we evaluated GSDMB expression and its splicing variants
in breast cancer tumors as well as normal mammary tissue by
qRT-PCR (Figure 1B, C) GSDMB gene expression was signifi-
cantly increased in breast carcinomas compared to normal
samples (p = 0.006) (Figure 1B). The comparative analysis of
GSDMB isoforms demonstrated that GSDMB-2 expression was
significantly increased in breast cancer tumors relative to normal
mammary tissue (p = 0.043), while the rest of GSDMB isoforms
did not show statistically significant differences (Figure 1C).
These data indicate that high levels of GSDMB expression are
associated with poor disease outcome (both disease free survival
and distant metastasis free survival) in breast carcinomas. Among
Figure 1. Expression of GSDMB in breast carcinoma and breast cancer cell lines. (A) Kaplan-Meier analysis of disease free survival (left) and
distant metastasis (right) in relation to GSDMB expression in breast carcinoma data sets [18–23]. Tumor samples were classified as GSDMBhigh
(carcinomas with the top 25% highest expression levels of GSDMB gene) and GSDMBlow (rest of the samples). Differences in survival between the
groups were assessed by log-rank test (p,0.0001). (B) Analysis of GSDMB expression in breast tumors samples (n = 18) and normal mammary tissue
(n = 4) by qRT-PCR. Median of GSDMB expression relative to b2 microglobulin as housekeeping gene is shown in blue (C) Analysis of the expression of
GSDMB splicing variants (GSDMB-1, -2, and 3&4) by qRT-PCR in the same breast tumors and normal tissue analyzed in B. Medians of expression
relative to b2 microglobulin as housekeeping gene are shown in blue. p-values shown were calculated by Wilcoxon rank sum test. (D) Quantitative
RT-PCR analyses of GSDMB in the indicated breast cell lines. Expression levels are relative to GAPDH. Bars represent the mean value 6 s.d. of two
independent experiments. (E) Analysis of GSDMB expression by western blot in the indicated cell lines. a-HSP90 was used as a loading control.
doi:10.1371/journal.pone.0090099.g001
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GSDMB isoforms, GSDMB-2 seems to be the most expressed
isoform in breast cancer tumors.
Additionally, we examined GSDMB expression in a panel of
breast cancer cell lines (MDA-231, MCF7, CAMA-1,T47D,
HCC1954) as well as non-tumorogenic cell line (MCF10-2A)
(Figure 1D-E). High-medium GSDMB mRNA expression levels
were detected in T47D and HCC1954 cell lines; by contrast
MDA-MB-231 and MCF7 showed low-levels of GSDMB.
Moreover, non-expression of GSDMB was detected in non-
tumorogenic cell line MCF10-2A (Figure 1D). Importantly, strong
protein expression was detected only in HCC1954 cells (Figure 1E),
which exhibit the highest levels of GSDMB mRNA.
Morphological and phenotypic changes after GSDMB-1
and -2 over-expression in the MCF7 breast cancer cell
line
To understand the implication of GSDMB overexpression in
breast cancer pathogenesis we first analyzed the phenotypic effect
of GSDMB over-expression on the MCF7 breast cancer cell line.
This cell line presents low mRNA expression level of all the
GSDMB isoforms (Figure S3 A) and no detectable GSDMB
protein expression [8] compared with HCC1954 cells (Figure 1E).
For this study we used GSDMB-2, the isoform most over-
expressed in breast cancer samples, and GSDMB-1 which was not
found significantly upregulated in the analyzed breast carcinoma
samples (Figure 1C).
For this purpose, we generated MCF7 stable transfectants by
over-expressing GSDMB-1 (MCF7-G1) and GSDMB-2 (MCF7-G2)
transcripts tagged with hemagglutinin epitope (HA) (Figure 2). The
overexpression of both isoforms was demonstrated at protein
(Figure 1A) and mRNA level (Figure 2B). Importantly, we
confirmed that exogenous expression of GSDMB-1 and -2
transfected cells was similar to the endogenous GSDMB expres-
sion levels observed in HCC1954 cells by western blot (Figure S3
B).
Interestingly, we observed that GSDMB-1/-2 over-expression
induced several morphological changes as demonstrated by the
increase of membrane projections (Figure 2C, panels c, d, e, f)
compared to control cells (Figure 2C, panels a, b). These results
suggest that GSDMB-1 and -2 over-expression leads to a re-
organization of membrane projections typical of a motile/invasive
cell phenotype.
In addition, immunofluorescence staining and confocal micros-
copy analysis showed that both isoforms were predominantly
present in the cytosol (Figure 2C). This is consistent with the
cytosolic localization of endogenous GSDMB in HCC1954 cell
line as shown by cell fractionation (Figure S3 C).
GSDMB over-expression promotes cancer cell migration
and invasion
To characterize further the effect of GSDMB on cell motility,
we performed barrier migration assays (Figure 3). We observed
that cells over-expressing GSDMB-1/-2 exhibited an increase in
Figure 2. Stable expression of GSDMB-1 and -2 in MCF7 breast carcinoma cell line induces phenotypic changes. (A) Analysis of
GSDMB-HA expression by western blot in control (MCF7-C), GSDMB1-HA (MCF7-G1) and GSDMB-2-HA (MCF7-G2) cells. a-tubulin was used as a
loading control. Two independent clones of GSDMB-1 (#7, #9) and GSDMB-2 (#4,#5) are shown. (B) Quantitative RT-PCR analysis of GSDMB-1 and -
2 in MCF7-C and GSDMB-1/2-transfected cells. Expression shown is relative to b2microglobulin that was used as housekeeping gene. (C) Phase-
contrast images of MCF7-C, MCF7-G1 and MCF7-G2 cells, x20 magnification (panels a, b, c respectively). Confocal immunofluorescence staining shows
the subcellular colocalization of GSDMB (GSDMB-HA in green) and Fibrilar-actin (in red) in MCF7-C, MCF7-G1 and MCF7-G2 cells (panels d, e, f). Bar
= 23.81 mm.
doi:10.1371/journal.pone.0090099.g002
Role of Gasdermin B in Breast Cancer
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90099
cell migration, demonstrated by their ability to migrate out of the
glass cover slip barrier, and by the formation of very dynamic cell
protrusions characteristic of migrating cells (Figure 3A, panels d, e,
g, h). In contrast, control cells were unable to move outside of glass
cover-slip barrier (Figure 3A, panels a, b). Although, the cell
migration dynamics of MCF7-G1 and MCF7-G2 were similar,
MCF7-G2 cells showed a more active migratory behavior than
MCF7-G1, 32 and 25 fold respectively (Figure 3B). Furthermore,
cells transfected with the isoform 1 showed a less cohesive
phenotype, evidenced by the formation of intercellular spaces
between cells (Figure 3A, panel e, f); while MCF7-G2 cells
appeared to have a more cohesive phenotype (Figure 3A, panels h,
i). Immunofluorescence analysis showed that the actin filament
network is distributed cortically in MCF7-G2 cells, and the
invasion front had active membrane projections, presumably to
generate the tracking force necessary for cell migration (Figure 3A,
panel i).
To rule out that the increased cell migration was due to higher
cell proliferation, we analyzed the proliferation of these cell lines
by 5-bromo-2’-deoxyuridine (BrdU) incorporation into DNA. We
did not find significant differences in the proliferation rate of the
different cell types (Figure 3C). Therefore, cell growth does not
seem to be contributing to the differences found in cell migration.
To determine if GSDMB over-expression increases cancer cell
invasion we performed matrigel-coated Boyden chamber invasion
assays. We found that GSDMB-1/-2 over-expression dramatically
increased the invasiveness of these cell lines compared to control
cells (,2.7 and ,3 fold, respectively) (Figure 4A).
To confirm that GSDMB promotes migratory and invasive
capacities in breast cancer cells, we analyzed the behavior of
HCC1954 after stable knockdown of GSDMB. Using two shRNAs
we efficiently knocked down GSDMB protein, by targeting various
isoforms at the same time (Figure S4 A). Importantly, GSDMB
repression resulted in a marked decrease of the migratory ability
(Figure S4 B) as well as the invasion capacity of HCC1954 cells
(Figure S4B), while the proliferation was not significantly affected
(Figure S4 A).
To further investigate the increased in the invasive behavior of
MCF7-GSDMB-1/-2 cells we evaluated their matrix degradation
capacity using gelatin degradation assays on FITC-labeled gelatin
(Figure 4B). We analyzed the local proteolytic activity by the
appearance of dark areas lacking fluorescence in the bright
fluorescent matrix. As shown in Figure 4B (panels a, d) degraded
Figure 3. Over-expression of GSDMB-1/-2 increases cell motility. (A) Analysis of cell motility in MCF7-C, MCF7-G1 and MCF7-G2 cells by barrier
assay. Images were taken at five days post-seeding. Panels a, d and g show phase-contrast images. Panels b-c, e-f, h-i show F-actin staining by
confocal immunofluorescence in the indicated cells. Cell nuclei were counterstained with DAPI (blue). Panels c, f and i show a magnification of the
morphology of migrating cells at the invasive front for each cell line. Bars = 150 mm middle panels, 61.16 mm right panels. (B) Quantification of the
migrated distance from the edge of the coverslip (in mm) in barrier assays. Bars represent the mean value 6 s.d. relative to control cells (MCF7-C) by
one-way ANOVA test **0.001,p,0.005. N= 3 independent experiments. (C) Proliferation assay by BrdU incorporation in MCF7-C control cells and
MCF7-G1 (#7,#9) and MCF7-G2 (#4,#5) transfectant clones. Bars represent the mean value6 s.d. by one-way ANOVA test; ns, non-significant. N = 3
independent experiments.
doi:10.1371/journal.pone.0090099.g003
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areas were scarcely detected in the control cells whereas in the
GSDMB over-expressing transfected cells a significantly increase
of these areas of degradation were observed (Figure 4B, panels b,
c, e, f). The staining with phalloidin revealed also that F-actin rich
cores extended from the basal surface of the cell into the cytosol
and often co-localized with areas of matrix degradation in MCF7-
G1 and MCF7-G2 cells (Figure 4B, panels e, f). The quantification
of the degraded area revealed that although all cell lines show
gelatinase activity, in MCF7-G2 cell line the degradation of
substrate was significantly increased (,7 fold), compared to
MCF7-G1 (,3.5 fold) as well as control cells as expected
(Figure 4C). These data indicate that GSDMB-2 over-expression
significantly increased proteolytic gelatinase activity.
It is well known that the extracellular matrix-degrading ability is
largely dependent on matrix metalloproteinases (MMPs), including
MT1-MMP, MMP-2, and MMP-9 [25,26]. Based in our gelatin-
based assays, we analyzed the secretion levels of different members
of the MMP family in zymogram assays, but we could only detect
the active form of MMP-9 (Figure 4D). Although both
transfectants showed an increase in the activity of MMP-9, the
quantification of observed differences was not significant (data not
shown). Then, we studied the expression of a panel of 10 different
proteases by RT-PCR. As shown in Figure 4E, we found an
increased expression of MT1-MMP, MMP-1 and MMP-10 in
GSDMB expressing clones compared to control cells. Interesting-
ly, we found that there is a specific pattern of MMPs depending on
the isoform: while MT1-MMP was overexpressed in both isoforms
relative to control cells, MMP-1 was upregulated in GSDMB-2
cells, and MMP10 was increased only in GSDMB-1 cells
(Figure 4E).
Collectively, our results suggest that GSDMB increases cell
migration and invasion possibly by up-regulating the secretion of
MMPs in an isoform-specific pattern.
GSDMB promotes Rho GTPases activation
To further investigate the function of GSDMB on cell
migration, we analyzed the activation of several Rho-GTPases
(Figure 5A-C). After pull down assays, we observed an increased
activation of Rac-1 and Cdc-42 in GSDMB-2 expressing cells
compared to control and to GSDMB-1 cells, as shown by higher
levels of GTP-bound GTPases (Figure 5B, C). However, non-
significant changes were observed in the Rho-A activation
Figure 4. GSDMB-1/-2 over-expression increases cell invasion and gelatin degradation. (A) Matrigel invasion assays of MCF7-C and MCF7-
G1 and MCF7-G2 cells; bars represent the mean value 6 s.d. by one-way ANOVA test **0.001,p,0.005;***p,0.001; ns, non-significant. N = 3
independent experiments by triplicate. (B) Representative confocal immunofluorescence images of fluorescent gelatin degradation assay in MCF7-C
and MCF7-G1 and MCF7-G2 cells after 8 hours. F-actin and nuclei were stained with 546-phalloidin (red) and DAPI (blue) respectively. Degraded areas
are visualized in black. Bar = 23.81 mm. (C) Quantification of the gelatin-degraded area in GSDMB-1/-2 cells. Bars represent the mean value 6 s.d.
relative to control cells (MCF7-C) by one-way ANOVA test **0.001,p,0.005; ns, non-significant. N = 3 independent experiments. (D) Zymogram of
MMP-9 and MMP-2 activity in the conditioned media from MCF7-C, MCF7-G1 and MCF7-G2 cells analyzed 24 hours after cell seeding. Graph shows
the quantification of the relative band intensities calculated by densitometry analysis as described in the Materials and methods section. (E) Semi-
quantitative RT-PCR analysis of the expression of MMP1, MMP10 and MT1-MMP in control MCF7-C cells and MCF7-G1 and MCF7-G2. GAPDH was used
as housekeeping gene.
doi:10.1371/journal.pone.0090099.g004
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(Figure 5A). In addition, confocal immunofluorescence assays
showed that Rac-1 staining was increased in GSDMB-2-express-
ing clones (Figure 5D, panels c, f) compared to control cells
(Figure 5D, panels a, d), suggesting a role for this protein in the
modification of motile structures. These findings are also in
agreement with the increase in actin filaments observed by
phalloidin staining in GSDMB-2 expressing cells (Figure 2C). To
determine the involvement of Rac-1 in GSDMB-mediated
migration, we performed migration assays in MCF7-GSDMB
and control cells treated with NSC23766, a well-known Rac-1
inhibitor [27] (Figure 5E). Rac-1 inhibitor partially suppressed
migration on MCF7-GSDMB-1 and GSDMB-2 cells, whereas this
inhibitor did not significantly affect control cells (Figure 5E).
Together, these data suggest that the significant increases in the
migration and invasion ability of GSDMB-2 cells could be related
to the capacity of activating Rac-1 and Cdc-42 GTPases
compared to GSDMB-1 and control cells.
GSDMB-2 increases the tumorigenic and metastatic
behavior in MCF7 cells
In order to validate the biological involvement of GSDMB-1
and -2 in breast cancer progression, we evaluated their in vivo effect
on tumor growth and metastasis using xenograft mouse models.
Firstly, to track tumor cells and monitor tumor growth and
metastasis, we stably over-expressed mCherry or luciferase proteins
in MCF7 control, GSDMB-1 and GSDMB-2 transfectant cells.
Analysis of tumor growth demonstrated that mice orthotopically
injected with GSDMB-2 cells developed significantly bigger
tumors (,6 fold) at the end of the experiment (33 weeks)
(Figure 6A, 6B), compared to control or GSDMB-1 cells.
Surprisingly, mice injected with GSDMB-1 cells developed tumors
smaller than the control group, although the difference was not
significant (Figure 6A, 6B). After 33 weeks, tumors were excised
and GSDMB expression was verified by immunohistochemistry
with anti-HA antibody observing strong cytoplasmic localization
of GSDMB-HA in the stable transfectant clones (Figure 6C, right
panels and inset). Importantly, the analysis of spontaneous
Figure 5. Rac-1 and Cdc-42 are activated in GSDMB-2 cells. Analysis of Rho A (A), Rac-1 (B) and Cdc-42 (C) activity by pull-down assays in
MCF7-C, MCF7-G1 and MCF7-G2 cells. Densitometric analysis of Western blots analyzing each RhoGTPase activity is shown in the upper graphs. Bars
represent the mean value 6 s.d. relative to control cells (MCF7-C) by one-way ANOVA test *p,0.05;***p,0.001; ns, non-significant. (D) Confocal
immunofluorescence analysis showing the localization of GSDMB-HA isoforms (green) and Rac-1 (red) in MCF7-C, MCF7-G1 and MCF7-G2 cells. Cell
nuclei were counterstained with DAPI (blue). Bar: 37.5 mm. (E) Quantification of the effect of Rac-1 inhibition in cell migration. Cells were incubated in
the absence of serum and treated with 100 mmol/L NSC23766 for 72 h. Untreated control cells were used for each condition. Bars represent the mean
value 6 s.d. relative to control cells (MCF7-C) by one-way ANOVA test *p,0.05; **0.001,p,0.005; *** p,0.001; ns, non-significant. N = 3
independent experiments.
doi:10.1371/journal.pone.0090099.g005
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metastasis by immunofluorescence (Figure 6D, left panels) and
qRT-PCR of mCherry expression (Figure 6D, right graph),
demonstrated that GSDMB-2 overexpression increases metastatic
burden of MCF7 cells by 24 fold compared to control and to
GSDMB-1 expressing cells (Figure 6D).
Furthermore, we evaluated the homing capacity and growth in
metastatic organs using MCF7 control, GSDMB-1 and -2, stably
expressing the protein luciferase and intracardially injected mice
(Figure 7). After 3 weeks post-injection, all mice exhibited clear
signs of distant metastatic lesions by luciferase imaging (Figure 7A,
panels d, e, f). Mice were sacrificed after 11 weeks post-injection
with large signs of metastatic dissemination by luciferase imaging
at multiple sites, such as brain, lungs, abdomen and femurs,
(Figure 7A, panels g, h, i). Representative ex vivo images of bones,
lungs, ovaries and brain metastasis are shown in Figure 7B. We
detected metastasis to lungs and bone-associated tissue in all mice
with frequencies greater than 60-70% (Figure 7B, Table 1).
Although all the cell lines showed a widespread pattern of spread,
metastases to the brain and ovaries were substantially increased in
GSDMB-2-injected mice, with frequencies greater than 90% in all
the tissues analyzed (Figure 7B, Table 1). In contrast, mice injected
with control cells showed metastases in only 20% of the ovaries
and 60% of the brains analyzed. A similar frequency of metastases
was observed in GSDMB-1 mice in both tissues (20% in ovaries
and 20% in brain) (Figure 7B, Table 1).
Taken together these data demonstrate that GSDMB-2 over-
expression leads to an increased tumorogenic and metastatic
behavior of MCF7 breast cancer cells, with enhanced metastatic
cell homing and growth in ovaries and brain.
GSDMB-2 is a novel client of Hsp90
To further characterize the functional role of GSDMB-1/-2 we
identified their potential interacting partners by immunoprecipi-
tation assays followed by mass spectrometry (MS; see Protocol S1
and S2 for detailed protocol). Using this approach, we identified
Fatty acid synthase (FAS), and the Heat shock protein 90 b
(Hsp90b) (Table 2), as new potential interacting partners of both
GSDMB-1 and -2 isoforms. To validate the interaction, we
performed analytical co-immunoprecipitation experiments using
HEK293T cells transiently expressing GSDMB-1/-2-HA
Figure 6. GSDMB-2 over-expression increases the tumorogenic and the metastatic capacity of MCF7 cells. (A) Analysis of primary tumor
growth after mammary fat pad injection of MCF7-C-LUC and MCF7-G1-LUC and MCF7-G2-LUC cells. Error bars represents the mean value 6 s.d.
**0.001,p,0.005 by two-way ANOVA. N= 5 mice per group (B) Representative bioluminescence images of mice injected with MCF7-C, MCF7-G1 and
MCF7-G2-luciferase cells at week 33. The color scale represents the photon flux (photons per second) emitted. (C) Representative images of
hematoxilin and eosin staining (left panels) and GSDMB-HA immunohistochemistry (right panels) in sections obtained from primary mammary
tumors of the cells indicated (x20 magnification). Insets (right) are x60 magnification of the corresponding selected areas. (D) Analysis of metastases
in mice injected with mCherry-cells (MCF7-C, MCF7-G1 and MCF7-G2). Representative images of mCherry protein expression (in red) within the lungs
are shown on the left. Cell nuclei were counterstained with DAPI (blue), x40 magnification. Graph on the right shows the mCherry mRNA expression
by qRT-PCR in the lungs of the indicated groups (right) relative to GAPDH.
doi:10.1371/journal.pone.0090099.g006
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(Figure 8A). We confirmed that GSDMB-1 and GSDMB-2
interact with Hsp90 (Figure 8A) although we could not validate
the interaction with FAS (data not shown). Next, to determine the
functional consequences of the interaction between GSDMB-1
and -2 and Hsp90, we tested whether their protein levels were
modified after treatment with the Hsp90 inhibitor 17-AAG
(Figure 8C, 8D). As control, we used Akt (a well-known Hsp90-
client affected by Hsp90 inhibition [28] and confirmed that its
protein levels decreased in a 17-AAG concentration-dependent
manner in all cell lines used (Figure 8A-D). Interestingly, we found
that GSDMB-2 protein showed a significant reduction after Hsp90
inhibition, while the GSDMB-1 levels were almost stable
(Figure 8C). These results demonstrate that GSDMB-1/-2 are
new Hsp90-interacting proteins, however only GSDMB-2 seems
to be a direct client of Hsp90, as its stability relies on Hsp90
activity.
Figure 7. Analysis of cell homing and metastases of GSDMB transfectants by luciferase imaging. (A) Representative bioluminescence
images of mice intracardially injected with luciferase-expressing MCF7-C (panels a, b, c), MCF7-G1 (panels d, e, f), and MCF7-G2 cells (panels g, h, j).
Images were obtained at 0, 3 and 11 weeks after cell injection. The color scale represents the photon flux (photons per second) emitted from tumor
cells. (B) Metastatic burden quantified by luciferin photon flux at 11 weeks after tumor injection (ovaries, bone, lungs and brain are shown) (C)
Quantification of the percentage of organs with metastases. N = 5 mice per group. All experiments were performed in duplicate using 5 mice per
experiment.
doi:10.1371/journal.pone.0090099.g007
Table 1. Metastasis incidence and frequency in multiple
organs after intracardiac injection of MCF7 control (C) and
transfected MCF7-G1 and MCF7-G2 cells.
MCF7-C MCF7-GSDMB-1 MCF7-GSDMB-2
Ovaries 2/10 (20%) 1/10 (10%) 9/10 (90%)
Bone 8/10 (80%) 6/10 (60%) 9/10 (90%)
Lung 9/10 (90%) 7/10 (70%) 8/10 (80%)
Brain 2/5 (40%) 1/5(20%) 5/5 (100%)
Number of organs affected in relation to all organs tested (in fraction and in
percentage).
doi:10.1371/journal.pone.0090099.t001
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Discussion
The novel Gasdermin family of proteins (GSDMA-D) has been
implicated in carcinogenesis and tumor progression [4–9]
although their exact molecular and cellular function in these
processes is not well known. Overall, previous literature proposed
that GSDMA is considered a tumor suppressor gene according to
its pro-apoptotic effect in cancer cells [2,4], while GSDMB gene,
which is up-regulated in some cancer types, might have a tumor-
promoting role [5–9]. However, the potential involvement of
GSDM genes in breast cancer has not been addressed before. Here
we demonstrate for the first time that high levels of GSDMB gene,
but not the other GSDM members, are associated to poor
prognosis (in terms of disease-free and metastasis-free survival) in
human breast carcinomas. Most importantly, we have uncovered
that GSDMB promotes a pro-invasive and pro-metastatic role in
breast cancer. Our work provide new clues about the role of
GSDMB and its isoforms in cancer: a) there is a differential
expression of GSDMB isoforms in breast cancer; b) GSDMB-1
and -2 trigger a pro-migratory and pro-invasive program in breast
cancer cells; c) silencing of GSDMB reduces the migratory and
invasive capacities in HCC1954 breast carcinoma cell line, d)
GSDMB-2 plays an active role in tumor growth and metastasis; e)
the identification of GSDMB-2 as a new interacting Hsp90
protein. All these new aspects of GSDMB will be discussed below.
Even though there are some previous reports focused on the
expression of GSDMB, the function and the hypothetical
relevance of GSDMB protein in breast cancer is still unknown.
Therefore, we decided to investigate the role of this protein in
breast cancer. The analysis of the expression of this molecule in
human breast cancer suggests that GSDMB is over-expressed in
breast carcinomas and it could be considered as a potential marker
in these tumors. In fact, patients with increased expression of this
molecule showed a reduced survival and increased metastatic
disease. Our analysis of specific isoforms reveals that GSDMB-2 is
significantly upregulated in a cohort of breast cancer tumors as
compared to other isoforms. These results suggest that GSDMB-2
could be responsible for the poor prognosis of tumors overex-
pressing GSDMB. Our data together with previous reports in
gastric cancer [7,8] indicate that GSDMB isoforms have
differential expression levels within tumors and in normal tissues,
and importantly, they may have distinct cellular localization and
biological functions. Indeed, in MCF7 cells, both GSDMB
isoforms are mainly detected in the cytoplasm, consistent with
the cytoplasmic distribution of the endogenous GSDMB detected
in HCC1954 cells and similar to the previously reported
localization in hepatocellular carcinomas and gastric tumors [7].
Nonetheless, GSDMB-1 has also been described to show nuclear
localization in cervix carcinomas [8].
Our analysis of GSDMB over-expression in the breast cancer cell
tumor model MCF7 demonstrates that it promotes cell motility,
invasion and metastasis whereas GSDMB silencing strongly
reduced migration and invasion in HCC1954 breast cell line.
Our results showed that GSDMB-1 and -2 may play a differential
role in breast cancer. While the isoform 2 (GSDMB-2) seems to
drive a tumorogenic and metastatic behavior in MCF7 cell line in
vitro and in vivo, GSDMB-1 demonstrated a milder effect and could
only be observed in vitro. In fact, it was reported that over-
expression of GSDMB-1 transcript did not promote tumorogenesis
in nude mice using CHO cell line [8].
The differences in tumorogenicity between GSDMB-1 and 2
are surprising, as these isoforms differ only in exon 7, which is not
present in isoform 2 (Figure S1). Although the functional relevance
of exon 7 is unclear, based on our results, we hypothesize that the
alternative use of this exon could enable the coordination of
specific biological programs within the cell, given that the levels of
exogenous expression in MCF7 cells of both isoforms are similar
(at mRNA and protein levels). However, further data will be
required to demonstrate this hypothesis.
The differences in the in vivo behavior between MCF7 cells
expressing GSDMB isoforms 1 and 2 could be explained in part by
the distinct activation of pro-migratory and pro-invasion molecules
and pathways observed in vitro. Thereby, GSDMB-2 but not
GSDMB-1 promotes activation of Rac-1 and Cdc-42. It is well
established that Rac-1 and Cdc-42 proteins, which are frequently
upregulated in human cancers, including breast cancer, contribute
to tumor progression and metastasis [29–32]. Our data suggest
that GSDMB-2 could promote increased cell migration in vivo
through a Rac-1/Cdc-42- dependent mechanism, although we
could not find a direct interaction with these proteins (data not
shown). In addition to Rho GTPases, other molecules directly
involved in breast cancer invasion and metastasis such as MMPs
are differentially expressed after isoforms 1 and 2 over-expression.
Activation of these molecules may contribute to the enhanced
tumorogenicity and metastatic ability of GSDMB-2.
In addition to these intrinsic factors, GSDMB-2 may also
activate extrinsic signals in the surrounding tissue that allow cancer
cells to invade or colonize. It is worth noting, that while neither
GSDMB-1 nor GSDMB-2 increases proliferation of MCF7 cells,
GSDMB-2 promotes lung metastasis when injected in the
mammary fat pad. As MCF7 cells are weakly metastasic in
hormonally intact nude mice [33-35], in order to study the full
metastatic potential of GSDMB-expressing cells, we performed
intracardiac injection, which allows MCF7 cells to metastatize to
multiple organs, including bones, lung, brain, and lymph nodes
among others [36–37]. Using this system, GSDMB-2-expressing
cells significantly increased the colonization of multiple organs
such as brain, lungs, bones and ovaries, compared to GSDMB-1
Table 2. Peptides identified after immunoprecipitation




Name number KDa LSFFFDFR //






Hsp90 P08238 90 289 IDIIPNPQER //








*Score is a parameter characterizing identification reliability of a certain protein.
In general, at score value .60–70, identification may be considered as reliable.
doi:10.1371/journal.pone.0090099.t002
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and control cells. Taking together all this data it is conceivable that
GSDMB-2 over-expression confers an advantage required for
metastatic dissemination.
The biological function of GSDMB is largely unknown,
probably due to the lack of obvious functional domains. Moreover,
to date the mechanisms controlling its stability and its potential
interacting partners are unknown. In this sense our immunopre-
cipitation and mass spectrometry assays demonstrated that Hsp90
protein interacts with GSDMB-1 and 2. As Hsp90 and its related
co-chaperones play a regulatory role in maintaining conforma-
tional maturation and structural integrity of a variety of cellular
proteins [38–39], we analyzed if GSDMB could be a new client
protein of this chaperone. Moreover, using in silico docking analysis
we found that although both isoforms are hypothetically able to
interact with Hsp90, the interaction between GSDMB-2 and
HSP90 seems to be more energetically favorable (data not shown).
More interestingly, we validated this study corroborating that,
GSMDB-2 but not GSDMB-1 protein levels are regulated in an
Hsp90-dependent manner. These data could suggest that the
differential role of both isoforms could be attributed to the lack of
this specific region, although this hypothesis remains to be
demonstrated. Indeed, different studies have demonstrated that
alternative splice isoforms of the very same kinase sometimes show
striking differences in Hsp90 binding, suggesting that a distributed
set of residues is required for robust Hsp90 association [40].
According to our results, Hsp90 inhibition could therefore be a
novel mechanism to block GSDMB-2 and its tumorigenic
potential.
In summary, we have shown that GSDMB up-regulation in
breast cancer associates to poor prognosis and increased metas-
tasis. The molecular mechanisms promoting GSDMB over-
expression in breast carcinomas, though, remains to be elucidated.
In gastric tissue, it has been suggested that cellular and viral origin
LTR promoters could selectively control GSDMB expression in
normal and cancer tissues, respectively [9,41,42], and that an Alu
element, located in the upstream region of GSDMB gene, could be
also responsible for GSDMB up-regulation [9]. Moreover,
GSDMB gene amplification has been reported in a small subset
of gastric carcinomas [5]. Whether similar mechanisms occur in
breast cancer, will be the focus of future research. Independently
of the mechanism of over-expression, we have demonstrated for
the first time that GSDMB is functionally involved in breast cancer
Figure 8. GSDMB-1 and GSDMB-2 interact with Hsp90 protein. (A) Immunoprecipitation assay of GSDMB-HA (left panel) and Hsp90 (right
panel) in HEK293T cells transiently transfected with HA-tagged GSDMB-1 (HEK.G1) and GSDMB-2 (HEK.G2). After immunoprecipitation, specific
interactions were detected using Hsp90 (a-Hsp90) and GSDMB (a-GSDMB) antibodies. (B, C, D) Analysis of protein levels by Western blot after
treatment with the Hsp90 inhibitor 17 AAG (1,000, 500, 100, and 50 nmol/L) for 24 hours in MCF7-C cells (B), MCF7-G1 (C) and MCF7-G2 (D). GSDMB
was detected using anti-HA antibodies. Akt detection was performed as positive control for Hsp90 inhibition. Densitometric analyses of the Wertern
blots are shown in the right graphs. Bars represent the mean value6 s.d. relative to control (DMSO) by one-way ANOVA test followed by Bonferroni’s
posttest. *p,0.05; **0.001,p,0.005; *** p,0.001; ns, non-significant. N = 3 independent experiments.
doi:10.1371/journal.pone.0090099.g008
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tumor aggressiveness and metastatic dissemination. Specific
isoforms of this molecule seem to have a differential role in cancer
and could be regulated by particular mechanisms. We propose
that GSDMB could be considered as a new marker of invasiveness
and metastasis in breast cancer, although additional studies will be
required to fully understand the molecular mechanisms involved.
Our work opens the way for future analysis of GSDMB proteins in
breast cancer tumor progression and metastasis.
Supporting Information
Figure S1 Schematic representation of the exon–intron
structure and the alternative splicing isoforms of the
human GSDMB gene. Schematic representation of the
GSDMB gene exon–intron structure (top) and the splicing
isoforms of the GSDMB gene as predicted by the NCBI database.
An arrow marks the translational start site of GSDMB in exon 2
(E2). Black boxes represent coding exons, grey boxes show
untranslated regions and introns are indicated by solid lines.
The alternative processing of the exon 6 (E6) and 7 (E7) in the
isoforms 1, 2 and 4 are represented by dotted lines.
(TIF)
Figure S2 Survival analysis of Gasdermin genes in
breast cancer. Association of the expression of Gasder-
min genes (GSDMA-D) with overall survival in 534
patients with breast cancer. Expression data was retrieved
from The Cancer Genome Atlas Network study [17] and plotted
as Kaplan Meier curves. For each gene, tumor samples were
classified as high (carcinomas with the top 25% highest expression
levels of GSDM genes) and low (the rest of tumors). Differences in
survival between the groups were assessed by log-rank test.
(TIF)
Figure S3 Comparison of endogenous versus exogenous
GSDMB protein levels and subcellular distribution. (A)
Quantitative RT-PCR analyses of the expression of all the GSDMB
isoforms in MCF10-2A, MCF7 and HCC1954 cells relative to
GAPDH expression. (B) Western blot analyses to determine the
relative amounts of endogenous protein levels of GSDMB (47 kDa)
in HCC1954 cells versus the corresponding overexpressed variants
(MCF7-G1 and MCF7-G2) and control cells (MCF7-C). GAPDH
expression was used as housekeeping gene. (C) Subcellular
fractionation and localization of endogenous GSDMB in
HCC1954 cells. Equal amounts of whole cell (WCE: lane 1),
cytoplasmic (CE: lane 2), membrane (ME: lane 3), nuclear (NE: lane
4), chromatin-bound (CB:lane 5) and cytoskeletal (PE: lane 6)
extracts were loaded and incubated with anti-GSDMB antibody.
The purity of these fractions was confirmed with antibodies against
Calnexin (membrane), HSP90 (cytoplasmic), Snail2 (nuclear),
HistoneH3 (chromatin-bound) and Cytokeratins (cytoskeletal).
(TIF)
Figure S4 GSDMB knockdown in HCC1954 cells reduces
the migration and invasion capacities. (A) GSDMB
expression in HCC1954 control cells (shControl) and in
shGSDMB-derived cells (sh108, sh794). (B) Quantitative RT-
PCR analyses of the expression of the different isoforms of GSDMB
in control (shControl) and two different shGSDMB (sh108, sh794)
generated in HCC1954 cells. (C) Cell proliferation was evaluated
using alamarBlue assay in control (shControl) and shGSDMB
(sh108, sh794) HCC1954 cells. Three independent experiments
are represented as mean 6 sd. Bars represent the mean value 6
s.d. by one-way ANOVA test; ns, non-significant. (D) Quantifi-
cation of transwell migration assay of shControl (shControl) and
shGSDMB- HCC1954 derived cells (sh108 and sh794); Bars
represent the mean value 6 s.d. relative to control (shControl) by
one-way ANOVA test *p,0.05; **0.001,p,0.005; *** p,0.001;
ns, non-significant. N = 3 independent experiments. (E) Invasion
assay on matrigel of control (shControl) and shGSDMB-
HCC1954 derived cells (sh108 and sh794); Bars represent the
mean value 6 s.d. relative to control (shControl) by one-way
ANOVA test *p,0.05; **0.001,p,0.005; *** p,0.001; ns, non-
significant. N = 3 independent experiments.
(TIF)
Table S1 Specific primers used for semiquantitative
PCR. Sequence of oligonucleotides, forward (F) and reverse (R),
for sqRT-PCR. The amplicon size is indicated in pair bases (pb).
sqRT-PCR conditions were optimized for each primer-pair.
Amplification reactions consisted of following steps: 95uC for
5 min, 25–30 cycles at 95uC for 30 sec; optimized annealing
temperatures for 30 sec and 72uC for 10 min.
(DOCX)
Table S2 Primers used for qRT-PCR. Reference of Taq-
man and SybGreen assays used in qRT-PCR. The manufactures
is indicated in the table.
(DOCX)
Protocol S1 Identification of proteins by Mass sectro-
metry (MS).
(DOCX)
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